2016 American Transplant Congress
TNT009 and Its Parental Mouse Monoclonal Antibody TNT003 Target Complement Component C1s and Effectively Block Alloantibody-Induced Classical Complement Pathway Activation – The Preclinical Experience.
Introduction. Considering the key role of the classical complement pathway as a trigger of inflammation and injury in antibody-mediated rejection (ABMR), targeted classical pathway inhibition…2015 American Transplant Congress
“Unexpected” Positive Crossmatchs in Zero-HLA-A-B-DR Mismatched or HLA-DR-Matched Organs
Deceased donor kidney allocation is currently prioritized by HLA-A,-B and-DR serologic matching, which disregards both specificity at the allele level, and the contributions of HLA-C,-DQ,…2015 American Transplant Congress
Protocol Donor Specific Antibody Monitoring After Kidney Transplantation: What Is the Utility?
De novo DSA has been shown to be a negative predictor of graft outcomes. However, the utility of routine DSA monitoring in the overall kidney…2015 American Transplant Congress
Does the C1q Assay Predict the Result of Lymphocyte Flow Cross-Match (FCxM) in Potential Renal Transplant Recipients With HLA-DSA and AHG-CDC CxM negative?
Background. The presence of pre-transplant HLA donor specific antibodies (DSA) is a recognized risk factor for acute rejection. However, due to the test's (LUMINEX) high…2015 American Transplant Congress
Number of Antigen Targets: A Key Parameter for Accurate Flow Cytometry Crossmatch Interpretation of Weak DSA
BACKGROUND: Flow cytometry crossmatch (FCXM) results are used to assess the safety of a transplant across pre-existing DSA. The number of targets on donor cells…2015 American Transplant Congress
Incidence of De Novo Donor Specific Antibodies in Kidney Transplant Recipients
The reported incidence and risk factors for the development of de novo donor specific antibodies (dnDSA) are variable. Although dnDSA is a negative predictor of…
American Transplant Congress abstracts